Navigation Links
Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results
Date:11/21/2011

SHENZHEN, China, Nov. 21, 2011 /PR Newswire-Asia/ – Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ("Global Pharm" or the "Company"), a growing vertically integrated pharmaceutical company engaged in the distribution of pharmaceutical-related products, Traditional Chinese Medicine ("TCM") processing, and herbal cultivation and sales in China through its subsidiaries in Anhui, Jilin, Guangdong and Shandong provinces, today announced its unaudited financial results for the third quarter ended September 30, 2011.

Third Quarter 2011 Highlights

  • Net revenues were $69.0 million, an increase of 125.4% as compared to the third quarter of 2010.
  • Gross profit was $9.6 million, an increase of 62.1% as compared to the third quarter of 2010, with gross margin of 13.9%.
  • Operating income was $6.1 million, an increase of 449.8% as compared to the third quarter of 2010.
  • Net income was $3.7 million, or $0.12 per diluted share, as compared to net loss of $0.07 million, or nil per diluted share, for the same period in 2010.
  • In July 2011, Global Pharm successfully acquired a TCM herbal pieces processing plant in Bozhou, Anhui Province.
  • In August 2011, Global Pharm successfully acquired a city-level pharmaceutical distributor in Weifang, Shandong Province. Furthermore, through its acquisition in August 2011 of the management and supply distribution rights to one of the largest pharmaceutical franchise of drugstores in Guangdong Province, the Company currently manages over 1,200 retail and chain drugstores in the area.
  • In September and October 2011, the Company issued redeemable convertible bonds in the aggregate principal amount of $15,000,000 to Blazer Delight Limited, an investment vehicle owned by a fund managed by Asia-based Gen2 Partners Limited.

  • "We're pleased to report a successful quarter marked by strong financial performance and important operational achievements. During the third quarter of 2011, we have further expanded our distribution network coverage in Shandong Province and Guangdong Province through new acquisitions, and completed the $15,000,000 convertible bonds financing, the proceeds of which will be used for our future growth," stated Mr. Yunlu Yin, Chief Executive Officer of Global Pharm.Third Quarter 2011 Financial Summaries (unaudited)Three months ended September 30(in millions $, except per-share data in $)

    2011

    2010

    % ChangeNet Revenue

    $69.0

    $30.6

    125.4%Gross Profit

    9.6

    5.9

    62.1%Income from operation

    6.1

    1.1

    449.8%Income before income taxes

    5.3

    1.1

    378.4%Net Income (loss)

    3.7

    (0.07)

    -Total comprehensive income

    3.4

    (0.2)

    -Diluted earnings per share

    0.12

    -

    N/ATotal net revenue was $69.0 million for the three months ended September 30, 2011, an increase of 125.4%, as compared with the same period in 2010. The increase was primarily due to the additional revenue contributed by the distribution business of our newly-acquired subsidiaries in 2011, amounting to $23.6 million, and the increased sales of $11.9 million by Shandong Global Pharm Group, Ltd. ("Shandong Global").

    Below is a breakdown of sales per business segment for the three months ended September 30, 2011 and 2010, respectively:

    For the three months ended September 30 – Revenue (unaudited)in US $ except percentage

    2011

    2010

    Change% of revenue% of revenue%Pharmaceutical products distribution

    $ 62,651,819

    90.8

    $ 24,810,775

    81.0

    $  37,841,044

    152.5TCM processing and distribution

    5,564,765

    8.1

    4,465,935

    14.6

    1,098,830

    24.6Herbal cultivation and sales

    782,509

    1.1

    1,341,110

    4.4

    (558,601)

    (41.7)Total

    $  68,999,093

    100.0

    $ 30,617,820

    100.0

    $  38,381,273

    125.4Revenue from the pharmaceutical products distribution segment increased by $37.8 million, or approximately 152.5%, to $62.7 million for the three months ended September 30, 2011, as compared to $24.8 million for the same period in 2010. The increase was primarily due to the additional revenue contribution from our four newly-acquired distribution subsidiaries in 2011. Revenue from the Company's TCM processing and distribution segment increased to $5.6 million for the third quarter of 2011, as compared to $4.5 million for the comparable period in 2010. The increase is mainly due to $2.5 million in additional revenue from our newly-acquired subsidiary, Bozhou Xinghe Pharmaceutical Co., Ltd. ("Bozhou Xinghe"), offset by an approximately $1.0 million decrease in the revenue of our other subsidiary, Anhui Xuelingxian Pharmaceutical Co., Ltd. ("Xuelingxian"). Our flower tea bags operations have been suspended since April 25, 2011, as such, we had nil revenue from this business, as compared to sales of $0.8 million for the three months ended September 30, 2010. Revenue from our herbal cultivation and sales segment was $0.8 million for the three months ended September 30, 2011, a decrease of approximately $0.6 million, or 41.7%, as compared to $1.3 million for the same period in 2010. The decrease was mainly due to reduced sales by Xuelingxian for three months ended September 30, 2011, because our herbal products were harvested in late September 2011 and sold after September 30, 2011, as compared to our earlier harvest of herbal products for the comparable period in 2010, of which some sales were recorded in the same quarter.

    Gross profit for the third quarter of 2011 was $9.6 million, an increase of 62.1%, from $5.9 million for the comparable period in 2010. Gross margin decreased to 13.9% for the third quarter of 2011 from 19.3%, for the comparable period in 2010, primarily attributable to the lower gross profit margin of our four newly-acquired subsidiaries, which had an average gross profit margin of 6.47%.

    Operating expenses for the third quarter of 2011 were $1.1 million, an increase of $0.7 million, as compared to the same period in 2010, primarily due to the additional operating expenses attributed to our newly-acquired subsidiaries in 2011, as well as to the increased advertising, freight and labor costs to support our business growth and expansion.

    Income from operation for the third quarter of 2011 increased 449.8% to $6.1 million, or 8.8% of total revenue, from $1.1 million, or 3.6% of total revenue for the comparable period in 2010.

    Net income for the third quarter of 2011 increased to $3.7 million, or $0.12 per fully diluted share, compared to a net loss of $72,376 for the same period in 2010, based on 28.9 million and 26.0 million weighted average diluted shares outstanding, respectively. This increase was primarily due to the one-time expense of the $3.0 million in stock-based compensation, which was recorded as general and administrative expenses in the three months period ended September 30, 2010, and had a significant impact on our net income. Nine Months 2011 Financial Summaries (unaudited) Nine months ended September 30(in millions $, except per-share data in $)

    2011

    2010

    % ChangeNet Revenue

    $156.2

    $90.2

    73.2%Gross Profit

    24.8

    16.6

    49.6%Income from operation

    18.2

    9.3

    95.5%Income before income taxes

    17.4

    9.3

    86.3%Net Income

    12.9

    5.7

    126.0%Total comprehensive income

    12.5

    5.6

    124.4%Diluted earnings per share

    0.47

    0.22

    113.6%Total net revenue was $156.2 million for the nine months ended September 30, 2011, an increase of 73.2%, as compared to the same period in 2010. The increase was primarily due to the additional revenue contributed by our newly-acquired subsidiaries in 2011, amounting to $25.1 million, and the increased sales of $35.2 million and $6.0 million by our subsidiaries, Shandong Global Tonghua Tongdetang Pharmaceutical and Medicinal Material Co., Ltd. ("Tongdetang"), respectively.

    Below is a breakdown of our sales by business segment for the nine months ended September 30, 2011 and 2010, respectively:For the nine months ended September 30 – Revenue (unaudited)in US $ except percentage

    2011

    2010

    Change% of revenue% of revenue%Pharmaceutical products distribution

    $ 134,481,832

    86.1

    $ 68,183,762

    75.6

    $   66,298,070

    97.2TCM processing and distribution

    16,238,510

    10.4

    20,646,774

    22.9

    (4,408,264)

    (21.4)Herbal cultivation and sales

    5,447,635

    3.5

    1,345,969

    1.5

    4,101,666

    304.7Total

    $  156,167,977

    100.0

    $ 90,176,505

    100.0

    $   65,991,472

    73.2Revenue from the pharmaceutical products distribution segment increased by $66.3 million, or approximately 97.2%, to $134.5 million for the nine months ended September 30, 2011, as compared to $68.2 million for the same period in 2010. The increase was primarily due to the additional revenue contributed by our four newly-acquired subsidiaries in 2011, and the increased sales by Shandong Global and Tongdetang. Revenue from our TCM processing and distribution segment decreased to $16.2 million for the nine months ended September 30, 2011, as compared to $20.6 million for the comparable period in 2010. The decrease is mainly due to the decrease in Xuelingxian's revenue from its TCM processing and distribution operations, amounting to $3.2 million, offset against the $2.5 million in additional revenue from Bozhou Xinghe. Our flower tea bags operations have been suspended since April 25, 2011, as such, we had nil revenue from this business, as compared to sales of $3.7 million for the nine months ended September 30, 2010. Revenue from our herbal cultivation and sales segment was $5.4 million for the nine months ended September 30, 2011, as compared to $1.3 million for the comparable period in 2010, an increase of approximately $4.1 million, or 304.7%. The increase was mainly due to sales of our entire remaining inventory of herbal products harvested during 2010 in the first quarter of 2011, amounting to $4.7 million.

    Gross profit for nine months ended September 30, 2011 was $24.8 million, an increase of 49.6%, from $16.6 million for the same period in 2010. Gross margin decreased to 15.9% for the nine months ended September 30, 2011, from 18.4% for the comparable period in 2010. The decrease is primarily attributable to the lower gross profit margin of our newly-acquired subsidiaries, which had an average gross profit margin of 5.9%.

    Operating expenses for the nine months ended September 30, 2011 were $2.4 million, an increase of $1.7 million, as compared to the same period in 2010, primarily due to the additional operating expenses attributed to our newly-acquired subsidiaries in 2011.

    Income from operation for the nine months ended September 30, 2011 increased 95.5% to $18.2 million, or 11.6% of total revenue, from $9.3 million, or 10.3% of total revenue for the third quarter of 2010.

     Net income for the nine months ended September 30, 2011 increased to $12.9 million, or $0.47 per fully diluted share, as compared to $5.7 million, or $0.22 per fully diluted share, for the same period of 2010, based on 27.0 million and 26.0 million weighted average diluted shares outstanding, respectively.

    Financial ConditionAs of September 30, 2011, the Company had $18.6 million in cash and $34.1 million in accounts receivable, as compared to $4.3 million and $19.8 million as of December 31, 2010, respectively. The increase was consistent with the increase in sales. The net working capital was $31.9 million, as compared to $17.4 million as of December 31, 2010. As of September 30, 2011, the Company had $5.0 million in short-term debt, as compared to $2.0 million as of December 31, 2010. Shareholders' equity totaled $76.4 million as of September 30, 2011, as compared to $17.6 million as of the end of 2010.

    For the nine months ended September 30, 2011, the Company generated $6.0 million cash from operating activities, as compared to $3.2 million for the comparable period in 2010. The net income for the nine months ended September 30, 2011 was $12.9 million, an increase of $7.2 million from $5.7 million for the comparable period in 2010. In addition to net income, the cash generated from operating activities was the net effect of the increase in accounts receivables of approximately $6.2 million, the increase in inventories of $7.4 million, the increase of restricted cash and other current assets of $5.1 million, the increase in accounts payable and accruals of $5.1 million, and the increase in amounts due to related parties of $5.3 million. The Company used $1.0 million in investing activities for the nine months ended September 30, 2011, as compared to $0.02 million for the comparable period in 2010, primarily as a result of increased expenditures relating to acquisitions of new businesses and equipment. Net cash provided by financing activities was $9.0 million for the nine months ended September 30, 2011, as compared to $2.9 million used for the comparable period in 2010. The cash provided in financing activities for the nine months ended September 30, 2011 was due to our repayment of loans of $2.6 million and the proceeds received from our convertible bonds financing of $10.0 million. 

    Subsequent EventsOn October 20, 2011, the Company issued an additional redeemable convertible bond in the aggregate principal amount of $5,000,000 to Blazer Delight Limited, under the terms of the Subscription Agreement dated September 19, 2011, which the Company entered into with Mr. Yunlu Yin and Blazer Delight Limited, and the relevant Bond Instrument.

    On October 31, 2011, the Company completed the acquisition of the 100% equity interest of Qingdao Likang Pharmaceutical Co., Ltd, a city-level pharmaceutical distributor located in Qingdao, Shandong Province.

    Business OutlookGlobal Pharm will continue to selectively acquire more distributors which can complement our business. For the rest of 2011, the Company is focusing on the quality of its operations through undertaking measures to enhance its unified management systems, such as improving the integrated information, procurement and sales-team management systems, in order to leverage the resources of each business segment and create synergies across all of them.

    About Global PharmGlobal Pharm Holdings Group, Inc., a growing integrated pharmaceutical company, is engaged in the distribution of pharmaceutical-related products, Traditional Chinese Medicine (TCM) processing, and herbal cultivation and sales in China. The Company focuses on building regional distribution channels, as well as local capillary sales network with a high-margin product portfolio. Currently, its sales network covers Shandong, Jilin, Anhui and Guangdong provinces. Global Pharm seeks to establish an integrated value chain in the pharmaceutical industry through strategic acquisitions within the TCM production, pharmaceutical distribution and retail sectors. For further information, please visit the Company's corporate website at http://www.globalpharmholdings.com.

    Forward-looking StatementsCertain statements set forth in this press release contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. Such statements reflect the current view of our management with respect to future events and are subject to risks, uncertainties, assumptions and other factors as they relate to our industry, our operations and results of operations, plans for future facilities, capital-expenditure plans and any businesses that we may acquire. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the U.S. federal securities laws, we do not intend to update any of the forward-looking statements to conform them to actual results.

    For Additional Information ContactGlobal Pharm Holdings Group, Inc.
    Ms. Susan Liu
    Phone: +86-755-3693-9373
    Email: susanliu@globalpharmholdings.com

    –FINANCIAL TABLES FOLLOW—GLOBAL PHARM HOLDINGS GROUP, INCCONDENSED CONSOLIDATED BALANCE SHEETS      September 30, 2011 

     December 31, 2010 

    (unaudited) ASSETS 

      Current assets:

     

     

     Cash and cash equivalents

    $18,570,246

     

    $4,271,498Accounts receivable

    34,069,776

     

    19,771,619Inventories

    29,852,272

     

    16,058,760Due from related party

    194,708-Restricted cash

    3,781,418

     

    1,538,251Other current assets

    5,355,8511,326,660Total current assets

    91,824,271

     

    42,966,788Property, plant and equipment, net

    8,505,797210,665Intangible assets, net

    33,860,597

     

    -Goodwill

    27,043,851-Total assets$161,234,516 $43,177,453LIABILITIES AND SHAREHOLDERS' EQUITY 

      Current liabilities:Short-term loan

    $5,003,753

     

    $1,972,150Bank acceptance

    4,805,33921,212Accounts payable and other accrued liabilities

    39,900,624

     

    20,944,923Income and other taxes payable

    2,959,5551,728,499Due to related party

    6,729,332

     

    882,505Deferred income tax liabilities

    491,360

     

    -Total current liabilities

    59,889,963

     

    25,549,289Long-term loan

    1,563,673

     

    -Bond payable, net

    4,436,318

     

    -Derivative liabilities

    5,563,682

     

    -Contingent consideration, at fair value

    5,765,708-Deferred income tax liabilities, net of current

    7,653,272

     

    -Total liabilities

    84,872,616

     

    25,549,289 

     

     

     Shareholder's equity:

     

     

     Common stock, par value, $0.001 per share, 100,000,000 shares

    authorized, 37,283,185 and 26,000,000 issued and outstanding

    37,283

     

    26,000Additional paid-in capital

    55,089,340

     

    9,200,623Statutory surplus reserves

    1,310,701

     

    1,310,701Retained earnings

    19,445,014

     

    6,546,406Accumulated other comprehensive income

    137,618

     

    544,434Total shareholders' equity - Global Pharm Holdings Group, Inc.

    76,019,956

     

    17,628,164Non-controlling interests

    341,944

     

    -Total shareholders' equity

    76,361,900

     

    17,628,164Total liabilities and shareholders' equity$161,234,516 $43,177,453CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME(unaudited)Three months ended September 30,Nine months ended September 30,2011201020112010Revenues, net$68,999,093

    $30,617,820$156,167,977

    $90,176,505Cost of goods sold59,427,311

    24,711,477131,405,558

    73,622,656Gross profit9,571,782

    5,906,34324,762,419

    16,553,849Expenses:Operating expenses

    1,100,309

    360,5722,447,617

    725,424General and administrative

    2,370,710

    4,436,0824,136,902

    6,531,617Income from operations6,100,763

    1,109,68918,177,900

    9,296,808Other income and expensesInterest (expense) income

    (99,087)

    2,842(101,100)

    21,048Miscellaneous (expense) income

    (13,511)

    -(48,110)

    -Change in fair value of contingent consideration

    (665,708)

    -(665,708)

    -Income before income taxes5,322,457

    1,112,53117,362,982

    9,317,856Provision for income taxes

    1,589,240

    1,184,9074,468,365

    3,609,764Net income (loss) – including non-controlling interest3,733,217

    (72,376)12,894,617

    5,708,092Net loss – non-controlling interests2,664

    -3,991

    -Net income (loss) - Global Pharm Holdings Group, Inc.3,735,881

    (72,376)12,898,608

    5,708,092Other comprehensive incomeForeign currency translation adjustment

    (351,777)

    (174,718)(406,816)

    (142,492)Total comprehensive income (loss)$3,384,104

    ($247,094)$12,491,792

    $5,565,600Earnings per share of common stock:Basic earnings per share

    $0.13

    $-$0.48

    $0.22Diluted earnings per share

    $0.12

    $-$0.47

    $0.22Weighted-average outstanding common sharesBasic weighted-average outstanding common shares

    28,727,803

    26,000,00026,909,268

    26,000,000Diluted weighted-average outstanding common shares

    28,947,583

    26,000,00026,982,528

    26,000,000GLOBAL PHARM HOLDINGS GROUP, INCCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)Nine Months Ended September 30,20112010Cash flows from operating activities 

     

     Net income–including non-controlling interest

    $12,894,617

     

    $5,708,092Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     Depreciation and amortization

    672,729

     

    51,993Merger cost

    -

     

    750,000Stock-based compensation

    -

     

    4,476,300Change in fair value of contingent consideration

    665,708

     

    -Changes in operating assets and liabilities: 

     

     Accounts receivable

    (6,236,658)

     

    (4,683,793)Inventories

    (7,390,787)

     

    (14,211,786)Due from related party

    (29,576)

     

    -Restricted cash

    (2,161,403)

     

    -Other current assets

    (2,968,622)

     

    (199,796)Accounts payable and other accrued liabilities

    5,139,874

     

    11,014,731Income and other taxes payable

    183,235

     

    294,485Due to related party

    5,348,883

     

    -Deferred tax expenses

    (85,477)

     

    -Net cash provided by operating activities6,032,523

     

    3,200,226 

     

     

     Cash flows from investing activities 

     

     Purchase of property, plant and equipment

    (432,647)

     

    (22,044)Proceeds on sale of assets

    41,606

     

    -Acquisition of subsidiaries, net of cash acquired

    (555,305)

     

    -Net cash used in investing activities(946,346)

     

    (22,044) 

     

     

     Cash flows from financing activities: 

     

     Short-term loan borrowing

    -

     

    366,763Short-term loan repayments

    (2,616,506)

     

    -Bank acceptance

    1,308,357

     

    (199,545)Due from related party

    -

     

    24,603Due to related party

    -

     

    1,168,986Dividend paid to the former shareholders

    -

     

    (4,309,377)Cash received from convertible bond

    10,000,000

     

    -Contribution from non-controlling interest

    344,835

     

    -Net cash provided by (used in) financing activities9,036,686

     

    (2,948,570) 

     

     

     Net increase in cash and cash equivalents14,122,863

     

    229,612Effect of exchange rate changes on cash and cash equivalents175,885

     

    145,532Cash and cash equivalents - beginning of period4,271,498

     

    7,455,147Cash and cash equivalents - end of period$18,570,246

     

    $7,830,291    Supplemental disclosure of cash flow information: 

     

     Cash paid for interest

    $148,866

     

    $20,655Cash paid for income taxes

    $3,927,576

     

    $2,994,851 

     

     

     Supplemental disclosure of financing activities 

     

     Deferred Bond issuance costs in accounts payable

    $287,500

     

    $-Common stock issued for acquisitions

    $51,000,000$-
    '/>"/>

    SOURCE Global Pharm Holdings Group, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
    2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
    3. Directors Forum: PEPFAR and the Global AIDS Response
    4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
    5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
    6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
    7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
    8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
    9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
    10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
    11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/10/2016)... Calif. , Feb. 10, 2016 /PRNewswire/ ... a synergistic confluence of various technologies that ... propositions, previously unavailable. These opportunities create a ... convergence, in turn, drives the development of ... scenario is characterized by technology convergences, which ...
    (Date:2/10/2016)... PRINCETON, New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader ... of its Series D investment round on February 5, ... Haisco Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical ... Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and ...
    (Date:2/10/2016)... DIEGO , Feb. 10, 2016 ALSP, Inc. ... , MD as Consultant for Medical Affairs in preparation for ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased ... We look forward to working with an individual of such ... We look forward to drawing deeply on his broad experience ...
    Breaking Medicine Technology:
    (Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... three leading bottled water brand owners that topped the list as a result of ... optimize conversion. The premier brand was Tibet 5100, a top notch water company that ...
    (Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
    (Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
    (Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
    (Date:2/10/2016)... ... February 10, 2016 , ... A national ergonomics pioneer ... Expo event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the ... the longest running and largest worker's compensation event in Ohio, organizers of the ...
    Breaking Medicine News(10 mins):